Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Laekna, Inc. ( (HK:2105) ) is now available.
Laekna, Inc. has announced the completion of the first visit for the first subject in its Phase I multiple ascending dose study of LAE102, a monoclonal antibody targeting obesity. This study aims to assess the safety and efficacy of LAE102, which has shown promise in pre-clinical models for increasing lean mass and decreasing fat mass, positioning it as a potential breakthrough in weight control therapies.
More about Laekna, Inc.
Laekna, Inc. is a biopharmaceutical company focused on developing precision therapies. The company specializes in monoclonal antibodies and aims to provide novel treatment options for conditions such as obesity.
YTD Price Performance: 48.99%
Average Trading Volume: 7,251,517
Technical Sentiment Signal: Strong Sell
For detailed information about 2105 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue